Hans Postlind
- Pharmacology top 0.2%
- Pharmacogenetics and Drug Metabolism 15
-
- Hormonal Regulation and Hypertension 11
- Hormonal and reproductive studies 1
- Oncology top 5%
- Drug Transport and Resistance Mechanisms 4
- Toxicology top 5%
- Genetics top 10%
- Estrogen and related hormone effects 5
-
- Vitamin D Research Studies 5
-
- Diet and metabolism studies 2
-
- Cancer therapeutics and mechanisms 1
- Co-authors
- Rolf OhlssonKristian SvenssonGöran BertilssonLena JendebergPatrik BlomquistAnders BerkenstamKjell WikvallRobert H. Tukey
- Journals
- Biochemical Journal (5 papers)Biochemical and Biophysical Research Communications (4 papers)Proceedings of the National Academy of Sciences (2 papers)
- Partner nations
- SwedenUnited States
In The Last Decade
Hans Postlind
19 papers receiving 1.4k citations
Hit Papers
Peers
Comparison fields: 5 of 90
- Pharmacology 805
- Endocrinology, Diabetes and Metabolism 393
- Oncology 457
- Toxicology 37
- Genetics 296
Countries citing papers authored by Hans Postlind
This map shows the geographic impact of Hans Postlind's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Postlind with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Postlind more than expected).
Fields of papers citing papers by Hans Postlind
This network shows the impact of papers produced by Hans Postlind. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Postlind. The network helps show where Hans Postlind may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hans Postlind, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. | 2007 | 236 |
| 2 | 2005 | 6 | |
| 3 | 2004 | 8 | |
| 4 | 2000 | 2 | |
| 5 | 2000 | 9 | |
| 6 | Biotransformation of tolterodine, a new muscarinic receptor antagonist, in mice, rats, and dogs. | 1998 | 21 |
| 7 | Identification of a human nuclear receptor defines a new signaling pathway for CYP 3 A inductionbreakdown → | 1998 | 726 |
| 8 | Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. | 1998 | 84 |
| 9 | 1997 | 31 | |
| 10 | 1996 | 10 | |
| 11 | 1995 | 15 | |
| 12 | 1994 | 57 | |
| 13 | 1993 | 134 | |
| 14 | 1992 | 26 | |
| 15 | 1991 | 20 | |
| 16 | 1990 | 12 | |
| 17 | 1990 | 17 | |
| 18 | 1989 | 13 | |
| 19 | 1988 | 13 |
About Hans Postlind
Hans Postlind is a scholar working on Pharmacology, Endocrinology, Diabetes and Metabolism and Pathology and Forensic Medicine, having authored 19 papers that have together received 1.4k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (15 papers), Hormonal Regulation and Hypertension (11 papers), Estrogen and related hormone effects (5 papers), Vitamin D Research Studies (5 papers), Drug Transport and Resistance Mechanisms (4 papers), Diet and metabolism studies (2 papers), Cancer therapeutics and mechanisms (1 paper) and Hormonal and reproductive studies (1 paper). The work is most often cited by research in Pharmacology (805 citations), Endocrinology, Diabetes and Metabolism (393 citations) and Oncology (457 citations). Hans Postlind has collaborated with scholars based in Sweden and United States. Frequent co-authors include Rolf Ohlsson, Kristian Svensson, Göran Bertilsson, Lena Jendeberg, Patrik Blomquist, Anders Berkenstam, Kjell Wikvall, Robert H. Tukey, Linda C. Quattrochi and Thai Vu. Their work appears in journals such as Biochemical Journal, Biochemical and Biophysical Research Communications, Proceedings of the National Academy of Sciences, Assay and Drug Development Technologies and FEBS Letters.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.